Drug Landscape ›
AST-120 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Hepatic Function Abnormal — 2 reports (16.67%) Renal Impairment — 2 reports (16.67%) Abdominal Pain Lower — 1 report (8.33%) Alanine Aminotransferase Increased — 1 report (8.33%) Amnesia — 1 report (8.33%) Anaemia — 1 report (8.33%) Ascites — 1 report (8.33%) Aspartate Aminotransferase Increased — 1 report (8.33%) Asthenia — 1 report (8.33%) Cardiac Failure Acute — 1 report (8.33%)
Source database →
AST-120 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is AST-120 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for AST-120 in United States?
Ocera Therapeutics is the originator. The local marketing authorisation holder may differ — check the official source linked above.